43(B)log (Free subscription) | yesterday
DePriest v. AstraZeneca Pharmaceuticals, L.P., --- S.W.3d ----, 2009 Ark. 547, 2009 WL 3681868 (Ark.) Plaintiffs sued AstraZeneca for false advertising of Nexium. Prilosec, Nexium’s predecessor, aka “The Purple Pill,” was AZ’s most profitable drug when its patent expired in 2001. In 2001, the FDA approved AZ’s request to market Nexium to treat conditions relating to gastro-esophageal...
The IN VIVO Blog (Free subscription) | 06/11/2009
Sweden’s Biovitrum on November 5 stumped up just over half a billion dollars for compatriot Swedish Orphan, buying itself a tidy additional SEK800 million ($115 million) in revenues, an extended commercial network and a couple of near-term launch opportunities. The move is yet another step in Biovitrum’s transformation into a specialty pharma company—coming just a week after it offloaded...
Pharmalot (Free subscription) | 06/11/2009
For years, there has been controversy over whether AstraZeneca pulled a fast one by touting Nexium as superior to Prilosec. Nexium and Prilosec, of course, are both sold by AstraZeneca and used to treat gastro-esophageal reflux disease (GERD), or heartburn. Many people bought the new prescription pill, but not everyone bought the marketing pitch. In [...]
MarketIntelligenceCenter.com (Free subscription) | 05/11/2009
AstraZeneca (NYSE: AZN) closed yesterday at $44.80. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 44.05 and resistance in the 45.51 range. Technical indicators for the stock are Bearish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income list. For...
SeekingAlpha ETFs (Free subscription) | 05/11/2009
Mike Havrilla submits: Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent...
Steve Clayton: Geek In Disguise (Free subscription) | 04/11/2009
Wow…I love the look of the new MSN homepage. You can check out the preview now . Very cool to see Twitter and Facebook integration and a clean, new logo. The MSN blog looks back at MSN homepages through the ages…scary that I can remember each and every iteration. Remember these two? Wow….how times have changed I was back working at Zeneca (now AstraZeneca) when these two pages...
1490 NewsBlog (Free subscription) | 03/11/2009
HARRISBURG - Attorney General Tom Corbett today announced that the Attorney General's Medicaid Fraud Control Section has recovered more than $1.5 million on behalf of the state's Medicaid program as part of a national agreement with three pharmaceutical companies involving drug pricing. Corbett said the settlements involve Mylan Pharmaceuticals, headquartered in West Virginia; AstraZeneca, based in...
Kevin, M.D. - Medical Weblog (Free subscription) | 03/11/2009
Originally published in Insidermedicine Second-generation antipsychotic drugs can produce unwanted weight gain and other metabolic effects among children and youths after only a few weeks, according to research published in the latest issue of the Journal of the American Medical Association. Here is some information about second-generation antipsychotic drugs: • Antipsychotics are [...] Posted...
MarketIntelligenceCenter.com (Free subscription) | 03/11/2009
AstraZeneca (NYSE: AZN) closed yesterday at $44.43. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 43.95 and resistance in the 44.91 range. Technical indicators for the stock are Bearish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income list. For...
PharmaGossip (Free subscription) | 03/11/2009
via thepoptort.com This all just adds to the point we try to make as often as we can: litigation doesn’t stifle innovation within the pharmaceutical industry. What it does do, however, is make it expensive – hopefully too expensive – for them to put unsafe drugs on the market or promote them in unsafe ways. Posted via web from Jack's posterous
Market Wire (Free subscription) | 03/11/2009
PARSIPPANY, NJ (MARKET WIRE) CommonHealth today announced that EvoLogue, the organization's full-service consumer agency, won the gold in the "Best Overall Advertising Campaign in Consumer Press" category for a print campaign, created for AstraZeneca, at the 2009 MM&M Awards dinner held on Thursday, October 29th at Tavern on the Green in New York City.
The Triangle Business Journal (Free subscription) | 02/11/2009
Quintiles Transnational has signed an agreement to manage the majority of British pharmaceutical giant AstraZeneca’s phase I clinical trials. (AZN)
Business Wire (Free subscription) | 02/11/2009
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe. As a result of the alliance, Quintiles will assume the operational responsibilities for the majority of AstraZeneca’s...
MarketIntelligenceCenter.com (Free subscription) | 02/11/2009
AstraZeneca (NYSE: AZN) ended the last trading session at $44.91. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 44.30 and resistance in the 45.80 range. Technical indicators for the stock are Bearish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income...
PharmaGossip (Free subscription) | 01/11/2009
By Martha Rosenberg ( about the author ) Page 1 of 2 page(s) opednews.com Permalink For OpEdNews: Martha Rosenberg - Writer Raise your hand if you've breathed a sign of relief seeing your doctor had a CME certificate next to the medical school diploma on the wall. Did your doctor pass , Bipolar Disorder: Individualizing Treatment to Improve Patient Outcomes, Part 2 "taught" by Trisha Suppes,...
Videos